|Bid||0.0750 x 0|
|Ask||0.0800 x 0|
|Day's Range||0.0700 - 0.0800|
|52 Week Range||0.0650 - 0.2250|
|Beta (5Y Monthly)||0.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr. 22, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Pascal Biosciences Inc. (TSX.V:PAS) ("Pascal") has entered into a Term Sheet with SōRSE Technology ("SōRSE") to develop Pascal’s cannabinoid programs. Investing in and financially supporting Pascal Biosciences’ research marks the first step for SōRSE Technology moving into medical research applications. This partnership leverages SōRSE’s industry-leading formulation technology with Pascal’s cannabinoid programs for clinical trials, led by Patrick Gray and his team of world-class medical researchers.
In exchange for the exclusive right to negotiate a definitive agreement, SōRSE has agreed to purchase units of Pascal, each unit consisting of one share and one warrant of Pascal, for gross proceeds of US$250,000 on a private placement basis (the "Private Placement"). Pascal intends to use the proceeds of the Private Placement for working capital purposes.
Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) and Y-Biologics (together the “Companies”) today announced a research collaboration agreement for the discovery and development of novel bispecific antibodies for the treatment of leukemia. Under the terms of the agreement, Y-Biologics will contribute its novel bispecific antibody platform technology, ALiCE, and Pascal will utilize its proprietary antibodies.
Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) today revealed the mechanism whereby cannabinoids may directly aid in cancer treatment. Specific cannabinoids identified by Pascal scientists enhance the immunogenicity of tumour cells, rendering them more susceptible to recognition and elimination by the immune system.
Pascal announces that Dr. Patrick Gray, CEO, will present an update today on the Company’s lead cannabinoid-based drug candidate, PAS-403, at the Second Annual International Cannabinoid Derived Pharmaceuticals Summit taking place in Boston, MA. The Second Annual International Cannabinoid Pharmaceutical Conference brings together world leaders researching the discovery and development of drugs from cannabis. Dr. Gray will discuss PAS-403 for the treatment of glioblastoma, including the progression to preclinical development, development of a manufacturing process, and fulfillment of FDA-required studies for biochemistry, metabolism, and safety.
Pascal Biosciences Inc. (PAS.V) (“Pascal” or the “Company”), a drug discovery and development company, today announced the Company will present at the upcoming BIO International Convention taking place June 3-6 at the Pennsylvania Convention Center in Philadelphia. The BIO International Convention is the premier annual meeting for biotech and pharma, with more than 16,000 attendees gathering for partnering and networking opportunities. Kevin Egan, VP Business Development at Pascal, will provide a corporate overview presentation highlighting the Company’s therapeutic pipeline on Tuesday, June 4 at 4:30 p.m. EDT in Theater 2, Level 200.
Pascal Biosciences Inc. (PAS.V) (“Pascal” or the “Company”), a drug discovery and development company, today announced it has formed a clinical advisory board (“CAB”) of preeminent neuro-oncology experts to guide its PAS-403 therapeutic program. PAS-403 is Pascal’s clinical candidate for the treatment of glioblastoma, a devastating brain cancer with limited therapeutic options. “We are extremely fortunate to have assembled this world-renowned group of leading researchers and clinicians in the field of neuro-oncology,” said Dr. Patrick Gray, CEO of Pascal.
Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today provided a corporate update for the first quarter of 2019. “We’ve made significant strides since the start of 2019, and these advancements position Pascal well for the future,” said Dr. Patrick Gray, CEO of Pascal. Great progress has been made for Pascal’s clinical candidate for glioblastoma, PAS-403, as it advances toward clinical trials.